Incyte’s previously disclosed phase 3 win in relapsed or refract | In the phase 3 inMIND study, Monjuvi—added to Bristol ...

Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ...

NICE has backed Celgene’s Revlimid for routine NHS use in another indication, follicular lymphoma, as part of a chemotherapy-free regimen with Roche’s MabThera. The cost-effectiveness agency ...

Lenalidomide has demonstrated single-agent ... specifically neutropenia and thrombocytopenia. Follicular lymphoma is a very diverse disease, and decisions to treat in the frontline are made ...

Monjuvi, Revlimid and Rituxan improved progression-free survival among adults with relapsed or refractory follicular lymphoma, topline research showed.

Lisocabtagene maraleucel has been granted FDA approval for the treatment of patients with relapsed/refractory follicular lymphoma. Christopher Flowers, MD, MS, discussed the phase 2 ROSEWOOD trial, ...

Follicular lymphoma is a diverse disease ... such as bendamustine, bortezomib, lenalidomide and anti-CD20 agents (rituximab, ofatumumab and radioimmunotherapy). Finally, hematopoietic stem ...

Lisocabtagene maraleucel has been granted FDA approval for the treatment of patients with relapsed/refractory follicular lymphoma. In an interview with Targeted Oncology, John P. Leonard, MD, ...

Monjuvi is available under an accelerated approval to treat adults with relapsed or refractory diffuse large B-cell lymphoma.

Celgene has been having some problems developing new drugs, but its Revlimid is the world ... of R 2 in relapsed/refractory follicular and marginal zone lymphoma met primary endpoint in relapsed ...